What You Don't Know About Hyperbaric Oxygen Therapy

<div class="OutlineElement Ltr SCXO115968455 BCX2" style= "margin-left: 0px; direction: ltr;"> <p class="Paragraph SCXO115968455 BCX2" lang="EN-US" style= "font-weight: normal; font-style: normal; vertical-align: baseline; background-color: transparent; color: windowtext; text-align: left;" xml:lang="EN-US"><span class="TextRun SCXO115968455 BCX2" lang="EN" style= "color: windowtext; font-size: 11pt; font-family: Georgia, serif; line-height: 17px;" xml:lang="EN" data-contrast="auto"><span class= "NormalTextRun SCXO115968455 BCX2" style= "background-color: inherit;">Join Dr. Jeffrey Gladden, Steve Reiter and Dr. Paul Harch in this episode of the Gladden Longevity podcast. Paul G. Harch, M.D. is a clinical private practice and academic physician who made a discovery in 1989 treating divers with chronic brain decompression illness.  He found that the wounds in these divers’ brains were similar to chronic extremity wounds, but they were only responsive to a non-traditional dose of hyperbaric oxygen therapy. In 2004, based on the life-extending outcomes of treating patients with dementia, he proposed the longevity potential of HBOT to the American Academy of Anti-Aging Medicine.  In March 2020, he proved the efficacy of HBOT in mild TBI persistent post-concussion syndrome in a randomized controlled trial and proposed HBOT application to COVID. Now in its 3</span></span><span class="TextRun SCXO115968455 BCX2" lang="EN" style= "color: windowtext; font-size: 8.5pt; font-family: Georgia, serif; line-height: 17px;" xml:lang="EN" data-contrast="auto"><span class= "NormalTextRun Superscript SCXO115968455 BCX2" style= "vertical-align: super; background-color: inherit;" data-fontsize= "11">rd</span></span> <span class="TextRun SCXO115968455 BCX2" lang="EN" style= "color: windowtext; font-size: 11pt; font-family: Georgia, serif; line-height: 17px;" xml:lang="EN" data-contrast="auto"><span class= "NormalTextRun SCXO115968455 BCX2" style= "background-color: inherit;">edition, HBOT is explained as an epigenetic therapy with expec